SARTORIUS AG O.N.
stock DE:SRT (FRANKFURT)

Alternative ID: DE0007165607 716560

Watch List

Exchange: FRANKFURT
Sector: Healthcare
Industry: Medical Instruments & Supplies
Market Cap: Large (23.17B)
Data in EUR

EPS: 3.84
Current PE: 0.99
BVPS: 18.04
Price/BVPS: 0.22
Dividend: 0.70 / 0.2%

Hist Grade: A+ (96.85)
YOY Grade: B (70.12)
Debt/FCF: 3.45
ROIC: 5.7%
PEG: 0.03
PEGY: 0.03

Value Price: 398.98
MOS Price: 199.49
MOS %: 10,000.8%
Graham Number: 39.45
Graham MOS %: 898.8%
IRT: 0.00

Market Price

3.95

0.16 4.2%

as of Mar 21 '23

52 Week Range:

3.34 414.50

Stock Analyzer Tutorials

General Info

type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

Financial Statements

type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

Growth Grade and Financial Ratios

type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

Price Charts

type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Exchange: FRANKFURT
Sector: Healthcare
Industry: Medical Instruments & Supplies
Market Cap: Large (23.17B)
Inst. Ownership: 2.81%
Insider Ownership: 88.09%
Full Time Employees: 13832

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement

Cash Flow Statement

Balance Sheet

Liquidity Ratios

Current Ratio

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name	Dec '11	Dec '12	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
Equity (BVPS)	4.32	4.84	5.21	5.72	7.34	7.96	8.72	9.94	12.10	12.90	18.04
growth rate		12.0%	7.6%	9.8%	28.3%	8.5%	9.6%	14.0%	21.7%	6.6%	39.8%
Earnings BIT	79.05	96.49	114.36	128.45	210.41	246.43	261.88	299.50	362.09	510.73	932.99
growth rate		22.1%	18.5%	12.3%	63.8%	17.1%	6.3%	14.4%	20.9%	41.1%	82.7%
Avg.PE	6.33	23.04	13.83	44.18	101.42	38.17	62.87	69.13	95.55	109.51	109.51
growth rate		264.0%	-40.0%	219.5%	129.6%	-62.4%	64.7%	10.0%	38.2%	14.6%	0.0%
ROA	4.69	4.77	4.67	3.97	9.32	6.45	5.66	5.86	5.84	6.00	6.14
growth rate		1.7%	-2.1%	-15.0%	134.8%	-30.8%	-12.3%	3.5%	-0.3%	2.7%	2.3%
ROE	14.23	15.14	14.95	12.68	27.59	18.76	19.16	20.81	20.21	24.36	27.63
growth rate		6.4%	-1.3%	-15.2%	117.6%	-32.0%	2.1%	8.6%	-2.9%	20.5%	13.4%
ROIC	9.15	8.77	8.38	7.36	15.55	10.73	9.34	9.14	9.28	9.66	10.38
growth rate		-4.2%	-4.5%	-12.2%	111.3%	-31.0%	-13.0%	-2.1%	1.5%	4.1%	7.5%
Cur. Ratio	1.21	1.12	1.69	1.75	1.76	1.61	1.71	1.57	1.28	1.39	1.16
growth rate		-7.4%	50.9%	3.6%	0.6%	-8.5%	6.2%	-8.2%	-18.5%	8.6%	-16.6%
Quick Ratio	0.66	0.56	0.93	0.77	0.94	0.86	0.91	0.78	0.56	0.63	0.51
growth rate		-15.2%	66.1%	-17.2%	22.1%	-8.5%	5.8%	-14.3%	-28.2%	12.5%	-19.1%
Leverage	3.14	3.21	3.19	3.20	2.77	3.02	3.72	3.41	3.51	4.48	4.52
growth rate		2.2%	-0.6%	0.3%	-13.4%	9.0%	23.2%	-8.3%	2.9%	27.6%	0.9%
Balance Sheet	Dec '11	Dec '12	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
Acct.Receivable	116.00	126.00	153.00	151.41	208.56	267.46	312.39	326.45	326.16	342.20	458.20
growth rate		8.6%	21.4%	-1.0%	37.7%	28.2%	16.8%	4.5%	-0.1%	4.9%	33.9%
Acct.Payable	58.00	47.00	67.07	56.63	70.95	76.37	91.69	120.47	141.15	189.81	283.00
growth rate		-19.0%	42.7%	-15.6%	25.3%	7.6%	20.1%	31.4%	17.2%	34.5%	49.1%
Cur.Assets	278.00	315.00	368.25	436.09	477.38	587.62	672.03	753.95	851.01	1,209.31	1,796.80
growth rate		13.3%	16.9%	18.4%	9.5%	23.1%	14.4%	12.2%	12.9%	42.1%	48.6%
Total Assets	960.00	1,071.00	1,181.32	1,273.03	1,437.24	1,752.99	2,297.72	2,526.88	2,868.55	4,484.74	5,697.93
growth rate		11.6%	10.3%	7.8%	12.9%	22.0%	31.1%	10.0%	13.5%	56.3%	27.1%
Cash	41.00	40.00	51.88	40.56	52.80	62.03	59.42	45.16	54.44	203.44	342.81
growth rate		-2.4%	29.7%	-21.8%	30.2%	17.5%	-4.2%	-24.0%	20.5%	273.7%	68.5%
Inventory	103.00	126.00	138.96	145.94	189.78	222.18	246.12	321.70	412.68	557.29	892.83
growth rate		22.3%	10.3%	5.0%	30.0%	17.1%	10.8%	30.7%	28.3%	35.0%	60.2%
Cur.Liabilities	231.00	281.00	221.91	248.90	270.95	364.37	393.67	480.70	662.61	871.09	1,547.16
growth rate		21.7%	-21.0%	12.2%	8.9%	34.5%	8.0%	22.1%	37.8%	31.5%	77.6%
Liabilities	594.00	666.00	731.07	775.37	792.48	1,016.18	1,491.16	1,553.49	1,775.37	3,104.45	3,977.74
growth rate		12.1%	9.8%	6.1%	2.2%	28.2%	46.7%	4.2%	14.3%	74.9%	28.1%
LT Debt	269.00	242.00	356.28	359.88	346.79	433.03	869.83	878.54	822.16	1,826.34	1,649.09
growth rate		-10.0%	47.2%	1.0%	-3.6%	24.9%	100.9%	1.0%	-6.4%	122.1%	-9.7%
Equity	366.10	404.40	367.63	397.92	517.73	579.67	617.79	740.57	810.35	1,031.44	1,260.30
growth rate		10.5%	-9.1%	8.2%	30.1%	12.0%	6.6%	19.9%	9.4%	27.3%	22.2%
Common Shares	68.00	68.00	68.00	68.00	68.00	68.00	68.00	68.39	68.39	68.42	68.42
growth rate		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	0.0%
Cash Flow Statement	Dec '11	Dec '12	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
Capital Expenditures	39.00	63.00	56.01	86.14	111.44	148.76	197.10	233.18	225.57	240.25	407.17
growth rate		61.5%	-11.1%	53.8%	29.4%	33.5%	32.5%	18.3%	-3.3%	6.5%	69.5%
Cash Dividends	10.40	13.80	16.20	17.22	18.24	25.82	31.12	34.54	42.06	24.28	48.23
growth rate		32.7%	17.4%	6.3%	5.9%	41.5%	20.5%	11.0%	21.8%	-42.3%	98.7%
Cash From OA	79.00	53.00	103.26	129.69	125.36	170.42	206.51	244.52	377.19	511.53	865.81
growth rate		-32.9%	94.8%	25.6%	-3.3%	35.9%	21.2%	18.4%	54.3%	35.6%	69.3%
FCF per Share	0.59	0.03	0.42	0.40	0.91	-0.15	-3.41	0.44	1.29	4.56	6.13
growth rate		-94.9%	1,300.0%	-4.8%	127.5%	-100.0%	0.0%	100.0%	193.2%	253.5%	34.4%
FCF	27.00	-10.00	47.00	44.00	14.00	22.00	9.00	11.00	152.00	271.00	459.00
growth rate		-100.0%	100.0%	-6.4%	-68.2%	57.1%	-59.1%	22.2%	1,281.8%	78.3%	69.4%
Income Statement	Dec '11	Dec '12	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
Sales	733.00	846.00	791.56	891.17	1,114.75	1,300.30	1,404.57	1,566.03	1,826.97	2,335.66	3,449.22
growth rate		15.4%	-6.4%	12.6%	25.1%	16.6%	8.0%	11.5%	16.7%	27.8%	47.7%
Op.Income	53.00	64.00	114.36	128.45	210.41	246.43	261.88	299.50	362.09	510.73	932.99
growth rate		20.8%	78.7%	12.3%	63.8%	17.1%	6.3%	14.4%	20.9%	41.1%	82.7%
IBT	79.00	93.90	95.40	96.23	172.38	204.11	201.19	270.69	302.99	424.75	668.42
growth rate		18.9%	1.6%	0.9%	79.1%	18.4%	-1.4%	34.6%	11.9%	40.2%	57.4%
Net Income	53.00	64.00	52.42	48.49	126.30	102.93	114.73	141.34	156.69	210.10	318.89
growth rate		20.8%	-18.1%	-7.5%	160.5%	-18.5%	11.5%	23.2%	10.9%	34.1%	51.8%
EPS	0.61	0.71	0.77	0.71	1.85	1.50	1.67	2.06	2.29	3.07	4.66
growth rate		16.4%	8.5%	-7.8%	160.6%	-18.9%	11.3%	23.4%	11.2%	34.1%	51.8%
Gross Profit	357.00	416.00	384.60	422.76	551.75	631.80	706.84	803.60	941.10	1,206.39	1,838.93
growth rate		16.5%	-7.6%	9.9%	30.5%	14.5%	11.9%	13.7%	17.1%	28.2%	52.4%
R&D	44.30	49.00	47.71	43.56	52.51	59.42	68.78	78.20	95.59	108.43	139.88
growth rate		10.6%	-2.6%	-8.7%	20.6%	13.2%	15.8%	13.7%	22.2%	13.4%	29.0%

Quarterly Statements

Item Name	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22
Earnings BIT	237.40	260.29	278.70	276.10	272.40
growth rate		9.6%	7.1%	-0.9%	-1.3%
Balance Sheet	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22
Acct.Receivable	453.90	458.20	517.60	586.80	586.10
growth rate		1.0%	13.0%	13.4%	-0.1%
Acct.Payable	475.40	283.00	569.20	571.80	582.50
growth rate		-40.5%	101.1%	0.5%	1.9%
Cur.Assets	1,735.80	1,796.80	1,876.40	2,046.50	2,196.60
growth rate		3.5%	4.4%	9.1%	7.3%
Total Assets	5,685.90	5,697.93	5,931.00	6,247.50	7,090.80
growth rate		0.2%	4.1%	5.3%	13.5%
Cash	356.00	342.81	246.90	233.10	235.10
growth rate		-3.7%	-28.0%	-5.6%	0.9%
Inventory	804.70	892.83	978.00	1,093.90	1,213.60
growth rate		11.0%	9.5%	11.9%	10.9%
Cur.Liabilities	1,436.20	1,547.16	1,546.50	1,653.00	2,289.10
growth rate		7.7%	0.0%	6.9%	38.5%
Liabilities	3,970.80	3,977.74	3,965.60	4,007.70	4,581.10
growth rate		0.2%	-0.3%	1.1%	14.3%
LT Debt	1,682.60	1,649.09	1,646.40	1,621.00	1,585.80
growth rate		-2.0%	-0.2%	-1.5%	-2.2%
Equity	1,234.10	1,260.30	1,427.70	1,666.10	1,877.20
growth rate		2.1%	13.3%	16.7%	12.7%
Common Shares	68.40	68.42	68.40	68.40	68.40
growth rate		0.0%	0.0%	0.0%	0.0%
Cash Flow Statement	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22
Capital Expenditures	95.10	164.87	96.40	123.60	130.80
growth rate		73.4%	-41.5%	28.2%	5.8%
Cash Dividends	0.03	0.03	85.90
growth rate		0.0%	260,203.0%
Cash From OA	194.90	230.21	190.20	97.00	162.30
growth rate		18.1%	-17.4%	-49.0%	67.3%
FCF	99.80	65.35	93.80	-26.60	31.50
growth rate		-34.5%	43.5%	-100.0%	100.0%
Income Statement	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22
Sales	897.70	922.32	1,024.80	1,035.60	1,052.60
growth rate		2.7%	11.1%	1.1%	1.6%
Op.Income	237.40	260.29	278.70	276.10	272.40
growth rate		9.6%	7.1%	-0.9%	-1.3%
IBT	212.70	69.22	350.60	297.30	281.80
growth rate		-67.5%	406.5%	-15.2%	-5.2%
Net Income	105.60	23.49	205.60	165.80	154.20
growth rate		-77.8%	775.3%	-19.4%	-7.0%
EPS
growth rate
Gross Profit	486.30	480.33	538.20	533.70	556.10
growth rate		-1.2%	12.1%	-0.8%	4.2%
R&D	34.00	39.48	42.70	41.10	38.40
growth rate		16.1%	8.2%	-3.8%	-6.6%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A+ (96.85)

YOY Growth Grade:

B (70.12)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Dividend Yield: 0.2%
Beta: 0.46
Beta of 0.4581 suggests that the asset is less volatile than the rest of the market.
PE: 0.99
EY: 100.9%
PEG: 0.03
PEG Ratio of 0.03 suggests that stock is underpriced.
PEGY: 0.03
PEGY Ratio of 0.03 suggests that stock is underpriced.
Price/BVPS: 0.22
Price to BVPS Ratio of 0.22 suggests that stock is undervalued.

Profitability Ratios

ROE: 27.6%
Return on Equity (ROE) of 27.6% suggests that a company is doing well.
ROS: 27.1%
The value of Return on Sales depends on the business and/or industry. Usually the higher ratio the better.
ROA: 11.7%
Return on Assets (ROA). Low ratio usually means poor performance, or ineffective use of assets by management. High ratio usually means good performance.
ROI: 53.0%
Return on Investment (ROI) of 53.0% suggests that a company is doing well.
ROIC: 5.7%
Return on Invested Capital (ROIC) of 5.7% suggests that a company may not be able to fund future growth from within.

Liquidity Ratios

Current Ratio: 1.16
Current Ratio of 1.16 suggests that a company may not be able to pay off bills as rapidly as it should.
Quick Ratio: 0.52
Quick Ratio of 0.52 suggests that a company does not have enough cash to cover immediate liabilities.
Cash Turnover: 13.82
Turnover Of Cash Ratio of 13.82 suggests that a company may be vulnerable to creditors. As a result it may be unable to pay wages or utility bills.
Equity Ratio: 22.1%
Equity Ratio of 22.1% suggests that a company has high financing and debt service costs, not very attractive to investors.
Debt/Equity: 315.6%
Debt to Equity Ratio of 315.6% suggests that greater risk assumed by creditors, hence greater interest by them in the way the company is being managed.
Debt/FCF: 3.45
Debt/FCF of 3.45 suggests that a company does not have enough cash to pay off its long term debt within three years.

Efficiency Ratios

Avg Collection Period: 48.49
Average Collection Period of 48.49 days suggests that a company is doing well.
Inventory Turnover: 1.80
Inventory Turnover Ratio of 1.80 suggests a large inventory, a never-out-of-stock situation, perhaps some obsolete items, or it could indicate poor liquidity and possible overstocking of items.
Cash Flow Ratio: 4.77
Cash Flow Ratio of 4.77 suggests a company is doing OK, but lower inventory is generally viewed as a positive trend.
Profit Margin: 9.3%

Value Price

PE and EPS

	Historical	Current	Forward
PE	82.92	1.03	122.78
EPS / Growth		3.84

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 18.0%

Estimates	Pessimistic	Moderate	Optimistic
Rate of Return	15.0%
MOS Price %	50 %
Future EPS Growth	18.0%	18.0%	18.0%
Future PE	35.96	80.55	80.55
Future EPS	20.04	20.04	20.04
Value Price MOS %	178.11 4,409.1%	398.98 10,000.8%	398.98 10,000.8%
MOS Price	89.06	199.49	199.49
IRT	0.87	0.87	0.87

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Graham Number: 39.45
Graham MOS: 898.8%

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.